Portal de Periódicos da CAPES

The New Zealand Parkinson’s progression programme

2022; Taylor & Francis; Volume: 53; Issue: 4 Linguagem: Inglês

10.1080/03036758.2022.2111448

1175-8899

Michael R. MacAskill, Toni L. Pitcher, Tracy R. Melzer, Daniel J. Myall, Kyla‐Louise Horne, Reza Shoorangiz, Mustafa M. Almuqbel, Leslie Livingston, Sophie Grenfell, Maddie Pascoe, Ethan T. Marshall, Steven Marsh, Sarah E. Perry, Wassilios G. Meissner, Catherine Theys, Campbell Le Heron, Ross Keenan, John C. Dalrymple‐Alford, Tim Anderson,

Neurological disorders and treatments

We describe the New Zealand Parkinson's Progression Programme (NZP3), its goals, findings, and future plans. To date, 354 people with Parkinson's disease and 89 healthy older controls have participated over a 14-year period. A major focus of the programme has been the characterisation of current cognitive impairment, and the identification of biomarkers for its future emergence in people with Parkinson's. The programme has made significant contributions to the concept of mild cognitive impairment (MCI) in Parkinson's and the development and validation of standardised criteria for it. Brain imaging, both MRI and PET, has also been a focus, showing associations between increasing brain pathology and declining cognitive function. Additional biomarkers such as genetics, fluid biomarkers, eye movement, speech, and quantitative electroencephalography (EEG) are also under investigation. The programme has become a platform supporting many other avenues of research, from investigating the personal impacts of caregiver burden through to national-level epidemiology. To date, the programme has led to multiple journal publications and 17 completed and 9 ongoing PhDs, and many other postgraduate theses. It has led to the development of a skilled core of early-career through to senior researchers and clinicians. We discuss the future directions for the programme.